Inhibition of sirtuin 2 exerts neuroprotection in aging rats with increased neonatal iron intake

Neural Regeneration Research

Volumn 9, Issue 21, 2014, Pages 1917-1922

  Wang, Xi Jin ^a   Wang, Mei Hua ^a   Yang, Liu ^a   Bai, Jie ^a   Yan, Zhi Qiang ^b   Zhang, Yu Hong ^c   Liu, Zhen Guo ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c TONGJI UNIVERSITY   (China)

Author keywords

Aging; AK 7; Corpus striatum; Dopamine; Iron homeostasis disruption; Nerve regeneration; Neural regeneration; Neurotoxicity; NSFC grants; Parkinson s disease; Sirtuin

Indexed keywords

AK 7; CARBONYL IRON; DOPAMINE; ENZYME INHIBITOR; SIRTUIN 2; UNCLASSIFIED DRUG;

ABNORMAL BEHAVIOR; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; EXPERIMENTAL BEHAVIORAL TEST; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IRON INTAKE; MALE; NEUROPROTECTION; NEUROTOXICITY; NEWBORN; NONHUMAN; OPEN FIELD TEST; PARKINSON DISEASE; RAT; ROTAROD TEST;

EID: 84916640676     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.4103/1673-5374.145361     Document Type: Article

References (53)

1. Anand T, Rahi M, Sharma P, Ingle GK (2014) Issues in prevention of iron deficiency anemia in India. Nutrition 30:764-770.
2. Barnham KJ, Bush AI (2008) Metals in Alzheimer’s and Parkinson’s Diseases. Curr Opin Chem Biol 12:222-228.
3. Bolognin S, Messori L, Zatta P (2009) Metal ion physiopathology in neurodegenerative disorders. Neuromolecular Med 11:223-238.
4. Chopra V, Quinti L, Kim J, Vollor L, Narayanan KL, Edgerly C, Cipicchio Patricia M, Lauver Molly A, Choi Soo H, Silverman Richard B, Ferrante Robert J, Hersch S, Kazantsev Aleksey G (2012) The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington’s disease mouse models. Cell Reports 2:1492-1497.
5. Connolly BS, Lang AE (2014) Pharmacological treatment of Parkinson disease: a review. JAMA 311:1670-1683.
6. de Oliveira RM, Pais TF, Outeiro TF (2010) Sirtuins: common targets in aging and in neurodegeneration. Curr Drug Targets 11:1270-1280.
7. Dillin A, Kelly JW (2007) Medicine. The yin-yang of sirtuins. Science 317:461-462.
8. Donmez G, Outeiro TF (2013) SIRT1 and SIRT2: emerging targets in neurodegeneration. EMBO Mol Med 5:344-352.
9. Finkel T, Deng CX, Mostoslavsky R (2009) Recent progress in the biology and physiology of sirtuins. Nature 460:587-591.
10. Gan L, Mucke L (2008) Paths of convergence: sirtuins in aging and neurodegeneration. Neuron 58:10-14.
11. Gao HM, Hong JS, Zhang W, Liu B (2003) Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson’s disease. J Neurosci 23:1228-1236.
12. Graham DR, Sidhu A (2010) Mice expressing the A53T mutant form of human alpha-synuclein exhibit hyperactivity and reduced anxiety-like behavior. J Neurosci Res 88:1777-1783.
13. Guang K, Yang MQ, Lu ZY, Ding FX, Wang M (2012) Discharge pattern changes of the subthalamic nucleus and primary motor cortex in Parkinson’s disease rats. Zhongguo Zuzhi Gongcheng Yanjiu 16:2757-2761.
14. Gureviciene I, Gurevicius K, Tanila H (2009) Aging and α-synuclein affect synaptic plasticity in the dentate gyrus. J Neural Transm 116:13-22.
15. Han SH (2009) Potential role of sirtuin as a therapeutic target for neurodegenerative diseases. J Clin Neurol 5:120-125.
16. Harting K, Knöll B (2010) SIRT2-mediated protein deacetylation: An emerging key regulator in brain physiology and pathology. Eur J Cell Biol 89:262-269.
17. Hindle JV (2010) Ageing, neurodegeneration and Parkinson’s disease. Age Ageing 39:156-161.
18. Kalle AM, Mallika A, Badiger J, Alinakhi, Talukdar P, Sachchidanand (2010) Inhibition of SIRT1 by a small molecule induces apoptosis in breast cancer cells. Biochem Biophys Res Commun 401:13-19.
19. Kaur D, Peng J, Chinta SJ, Rajagopalan S, Di Monte DA, Cherny RA, Andersen JK (2007) Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol Aging 28:907-913.
20. Kidd PM (2000) Parkinson’s disease as multifactorial oxidative neurodegeneration: implications for integrative management. Altern Med Rev 5:502-529.
21. Klein RL, Dayton RD, Diaczynsky CG, Wang DB (2010) Pronounced microgliosis and neurodegeneration in aged rats after tau gene transfer. Neurobiol Aging 31:2091-2102.
22. Lavu S, Boss O, Elliott PJ, Lambert PD (2008) Sirtuins--novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov 7:841-853.
23. Lee DW, Andersen JK (2010) Iron elevations in the aging Parkinsonian brain: a consequence of impaired iron homeostasis? J Neurochem 112:332-339.
24. Li W, Zhang B, Tang J, Cao Q, Wu Y, Wu C, Guo J, Ling EA, Liang F (2007) Sirtuin 2, a mammalian homolog of yeast silent information regulator-2 longevity regulator, is an oligodendroglial protein that decelerates cell differentiation through deacetylating alpha-tubulin. J Neurosci 27:2606-2616.
25. Longo VD, Kennedy BK (2006) Sirtuins in aging and age-related disease. Cell 126:257-268.
26. Lozoff B, Georgieff MK (2006) Iron deficiency and brain development. Semin Pediatr Neurol 13:158-165.
27. Lu MJ, Wang SS, Zhu Y (2013) Microglia-mediated oxidative stress injury in a mouse model of Parkinson’s disease. Zhongguo Zuzhi Gongcheng Yanjiu 17:2001-2006.
28. Luthi-Carter R, Taylor DM, Pallos J, Lambert E, Amore A, Parker A, Moffitt H, Smith DL, Runne H, Gokce O, Kuhn A, Xiang Z, Maxwell MM, Reeves SA, Bates GP, Neri C, Thompson LM, Marsh JL, Kazantsev AG (2010) SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci U S A 107:7927-7932.
29. Manfredsson FP, Tumer N, Erdos B, Landa T, Broxson CS, Sullivan LF, Rising AC, Foust KD, Zhang Y, Muzyczka N, Gorbatyuk OS, Scarpace PJ, Mandel RJ (2009) Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther 17:980-991.
30. Maxwell MM, Tomkinson EM, Nobles J, Wizeman JW, Amore AM, Quinti L, Chopra V, Hersch SM, Kazantsev AG (2011) The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS. Hum Mol Genet 20:3986-3996.
31. Milne JC, Denu JM (2008) The Sirtuin family: therapeutic targets to treat diseases of aging. Curr Opin Chem Biol 12:11-17.
32. Olanow CW, Tatton WG (1999) Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci 22:123-144.
33. Outeiro TF, Marques O, Kazantsev A (2008) Therapeutic role of sirtuins in neurodegenerative disease. Biochim Biophys Acta 1782:363-369.
34. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, Kazantsev AG (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson’s disease. Science 317:516-519.
35. Pandithage R, Lilischkis R, Harting K, Wolf A, Jedamzik B, Lüscher-Firzlaff J, Vervoorts J, Lasonder E, Kremmer E, Knöll B, Lüscher B (2008) The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility. J Cell Biol 180:915-929.
36. Pfister JA, Ma C, Morrison BE, D’Mello SR (2008) Opposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activity. PLoS One 3:e4090.
37. Radlowski EC, Johnson RW (2013) Perinatal iron deficiency and neurocognitive development. Front Hum Neurosci 7:585.
38. Rhodes SL, Ritz B (2008) Genetics of iron regulation and the possible role of iron in Parkinson’s disease. Neurobiol Dis 32:183-195.
39. Saunders LR, Verdin E (2007) Sirtuins: critical regulators at the cross-roads between cancer and aging. Oncogene 26:5489-5504.
40. Snyder AM, Connor JR (2009) Iron, the substantia nigra and related neurological disorders. Biochim Biophys Acta 1790:606-614.
41. Southwood CM, Peppi M, Dryden S, Tainsky MA, Gow A (2007) Microtubule deacetylases, SirT2 and HDAC6, in the nervous system. Neurochem Res 32:187-195.
42. Stankiewicz J, Panter SS, Neema M, Arora A, Batt C, Bakshi R (2007) Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics 4:371-386.
43. Taylor DM, Balabadra U, Xiang Z, Woodman B, Meade S, Amore A, Maxwell MM, Reeves S, Bates GP, Luthi-Carter R, Lowden PAS, Kazantsev AG (2011) A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. ACS Chem Biol 6:540-546.
44. von Campenhausen S, Bornschein B, Wick R, Bötzel K, Sampaio C, Poewe W, Oertel W, Siebert U, Berger K, Dodel R (2005) Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsycho pharm 15:473-490.
45. Wang X, Chen S, Ma G, Ye M, Lu G (2005a) Genistein protects dopaminergic neurons by inhibiting microglial activation. Neuroreport 16:267-270.
46. Wang X, Chen S, Ma G, Ye M, Lu G (2005b) Involvement of proinflammatory factors, apoptosis, caspase-3 activation and Ca2+ disturbance in microglia activation-mediated dopaminergic cell degeneration. Mech Ageing Dev 126:1241-1254.
47. Wang XJ, Yan ZQ, Lu GQ, Stuart S, Chen SD (2007a) Parkinson disease IgG and C5a-induced synergistic dopaminergic neurotoxicity: Role of microglia. Neurochem Int 50:39-50.
48. Wang XJ, Liu WG, Zhang YH, Lu GQ, Chen SD (2007b) Effect of transplantation of c17.2 cells transfected with interleukin-10 gene on intracerebral immune response in rat model of Parkinson’s disease. Neurosci Lett 423:95-99.
49. Wang XJ, Zhang S, Yan ZQ, Zhao YX, Zhou HY, Wang Y, Lu GQ, Zhang JD (2011) Impaired CD200-CD200R-mediated microglia silencing enhances midbrain dopaminergic neurodegeneration: Roles of aging, superoxide, NADPH oxidase, and p38 MAPK. Free Radic Biol Med 50:1094-1106.
50. Werner HB, Kuhlmann K, Shen S, Uecker M, Schardt A, Dimova K, Orfaniotou F, Dhaunchak A, Brinkmann BG, Möbius W, Guarente L, Casaccia-Bonnefil P, Jahn O, Nave KA (2007) Proteolipid protein is required for transport of sirtuin 2 into CNS myelin. J Neurosci 27:7717-7730.
51. Xiong P, Chen X, Guo C, Zhang N, Ma B (2012) Baicalin and deferoxamine alleviate iron accumulation in different brain regions of Parkinson’s disease rats. Neural Regen Res 7:2092-2098.
52. Yankner BA, Lu T, Loerch P (2008) The aging brain. Annu Rev Pathol 3:41-66.
53. Yu XH, Tian XL, Li YY, Jiang WW, Qian L (2012) Effects of repetitive transcranial direct current stimulation on praxiology of rats with Parkinson’s disease. Zhongguo Zuzhi Gongcheng Yanjiu 16:4471-4475.